메뉴 건너뛰기




Volumn 29, Issue 5, 2007, Pages 638-643

Examining differences in weekly warfarin dose in patients with and without cancer

Author keywords

Anticoagulation; Cancer; Heparins; Monitoring; Tolerability; Warfarin

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; FLUOROURACIL; GEMCITABINE; WARFARIN;

EID: 34848899580     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318074dc46     Document Type: Article
Times cited : (5)

References (25)
  • 2
    • 0037067889 scopus 로고    scopus 로고
    • Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: A randomized controlled study
    • Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002;162:1729-1735.
    • (2002) Arch Intern Med , vol.162 , pp. 1729-1735
    • Meyer, G.1    Marjanovic, Z.2    Valcke, J.3
  • 3
    • 0037775584 scopus 로고    scopus 로고
    • Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer
    • Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146-153.
    • (2003) N Engl J Med , vol.349 , pp. 146-153
    • Lee, A.Y.1    Levine, M.N.2    Baker, R.I.3
  • 4
    • 0037111563 scopus 로고    scopus 로고
    • Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis
    • Prandoni P, Lensing AWA, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484-3488.
    • (2002) Blood , vol.100 , pp. 3484-3488
    • Prandoni, P.1    Lensing, A.W.A.2    Piccioli, A.3
  • 5
    • 0033708930 scopus 로고    scopus 로고
    • A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy
    • Palareti G, Legnani C, Lee A, et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost. 2000;84:805-810.
    • (2000) Thromb Haemost , vol.84 , pp. 805-810
    • Palareti, G.1    Legnani, C.2    Lee, A.3
  • 6
    • 0033850037 scopus 로고    scopus 로고
    • Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: A retrospective analysis
    • Hutten BA, Prins MH, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 2000;18:3078-3083.
    • (2000) J Clin Oncol , vol.18 , pp. 3078-3083
    • Hutten, B.A.1    Prins, M.H.2    Gent, M.3
  • 7
    • 4644221063 scopus 로고    scopus 로고
    • Buller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(Suppl 3):401S-428S.
    • Buller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(Suppl 3):401S-428S.
  • 8
    • 4644230820 scopus 로고    scopus 로고
    • Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(Suppl 3):204S-233S.
    • Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(Suppl 3):204S-233S.
  • 9
    • 0026726392 scopus 로고
    • Factors affecting the maintenance dose of warfarin
    • James AH, Britt RP, Raskino CL, et al. Factors affecting the maintenance dose of warfarin. J Clin Pathol. 1992;45:704-706.
    • (1992) J Clin Pathol , vol.45 , pp. 704-706
    • James, A.H.1    Britt, R.P.2    Raskino, C.L.3
  • 10
    • 0036785249 scopus 로고    scopus 로고
    • Patient-specific factors predictive of warfarin dosage requirements
    • Absher RK, Moore ME, Parker MH. Patient-specific factors predictive of warfarin dosage requirements. Ann Pharmacother. 2002;36:1512-1517.
    • (2002) Ann Pharmacother , vol.36 , pp. 1512-1517
    • Absher, R.K.1    Moore, M.E.2    Parker, M.H.3
  • 11
    • 21144448879 scopus 로고    scopus 로고
    • Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose
    • Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352:2285-2293.
    • (2005) N Engl J Med , vol.352 , pp. 2285-2293
    • Rieder, M.J.1    Reiner, A.P.2    Gage, B.F.3
  • 12
    • 0037012465 scopus 로고    scopus 로고
    • Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy
    • Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002;287:1690-1698.
    • (2002) JAMA , vol.287 , pp. 1690-1698
    • Higashi, M.K.1    Veenstra, D.L.2    Kondo, L.M.3
  • 13
    • 0036914221 scopus 로고    scopus 로고
    • Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance
    • Scordo MG, Pengo V, Spina E, et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther. 2002;72:702-710.
    • (2002) Clin Pharmacol Ther , vol.72 , pp. 702-710
    • Scordo, M.G.1    Pengo, V.2    Spina, E.3
  • 14
    • 0037194409 scopus 로고    scopus 로고
    • Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response
    • Rivory LP, Slaviero KA, Clarke SJ. Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br J Cancer. 2002;87:277-280.
    • (2002) Br J Cancer , vol.87 , pp. 277-280
    • Rivory, L.P.1    Slaviero, K.A.2    Clarke, S.J.3
  • 15
    • 0033812260 scopus 로고    scopus 로고
    • Optimizing the erythromycin breath test for use in cancer patients
    • Rivory LP, Slaviero K, Seale JP, et al. Optimizing the erythromycin breath test for use in cancer patients. Clin Cancer Res. 2000;6:3480-3485.
    • (2000) Clin Cancer Res , vol.6 , pp. 3480-3485
    • Rivory, L.P.1    Slaviero, K.2    Seale, J.P.3
  • 16
    • 0008615560 scopus 로고    scopus 로고
    • A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer
    • Williams ML, Bhargava P, Cherrouk I, et al. A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer. Br J Clin Pharmacol. 2000;49:485-488.
    • (2000) Br J Clin Pharmacol , vol.49 , pp. 485-488
    • Williams, M.L.1    Bhargava, P.2    Cherrouk, I.3
  • 17
    • 0027509399 scopus 로고
    • High clearance of (S)-warfarin in a warfarin-resistant subject
    • Hallak HO, Wedlund PJ, Modi MW, et al. High clearance of (S)-warfarin in a warfarin-resistant subject. Br J Clin Pharmacol. 1993;35:327-330.
    • (1993) Br J Clin Pharmacol , vol.35 , pp. 327-330
    • Hallak, H.O.1    Wedlund, P.J.2    Modi, M.W.3
  • 18
    • 19344366484 scopus 로고    scopus 로고
    • Systematic overview of warfarin and its drug and food interactions
    • Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165:1095-1106.
    • (2005) Arch Intern Med , vol.165 , pp. 1095-1106
    • Holbrook, A.M.1    Pereira, J.A.2    Labiris, R.3
  • 19
    • 32944475687 scopus 로고    scopus 로고
    • An adverse interaction between warfarin and fluoropyrimidines revisited
    • Saif MW. An adverse interaction between warfarin and fluoropyrimidines revisited. Clin Colorectal Cancer. 2005;5:175-180.
    • (2005) Clin Colorectal Cancer , vol.5 , pp. 175-180
    • Saif, M.W.1
  • 20
    • 0030799414 scopus 로고    scopus 로고
    • Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes
    • Ren S, Yang JS, Kalhorn TF, et al. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res. 1997;57:4229-4235.
    • (1997) Cancer Res , vol.57 , pp. 4229-4235
    • Ren, S.1    Yang, J.S.2    Kalhorn, T.F.3
  • 21
    • 0141539462 scopus 로고    scopus 로고
    • Fatal cholestatic liver failure associated with gemcitabine therapy
    • Robinson K, Lambiase L, Li J, et al. Fatal cholestatic liver failure associated with gemcitabine therapy. Dig Dis Sci. 2003;48:1804-1808.
    • (2003) Dig Dis Sci , vol.48 , pp. 1804-1808
    • Robinson, K.1    Lambiase, L.2    Li, J.3
  • 22
    • 0028357278 scopus 로고
    • Assessing random error in the international normalized ratio
    • Inciardi JF. Assessing random error in the international normalized ratio. Ther Drug Monit. 1994;16:425-426.
    • (1994) Ther Drug Monit , vol.16 , pp. 425-426
    • Inciardi, J.F.1
  • 23
    • 0017355290 scopus 로고
    • Warfarin elimination and responsiveness in patients with renal dysfunction
    • Bachmann K, Shapiro R, Mackiewicz J. Warfarin elimination and responsiveness in patients with renal dysfunction. J Clin Pharmacol. 1977;17:292-299.
    • (1977) J Clin Pharmacol , vol.17 , pp. 292-299
    • Bachmann, K.1    Shapiro, R.2    Mackiewicz, J.3
  • 24
    • 0036263813 scopus 로고    scopus 로고
    • Cytochrome P450 2C9 polymorphisms: A comprehensive review of the in-vitro and human data
    • Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics. 2002;12:251-263.
    • (2002) Pharmacogenetics , vol.12 , pp. 251-263
    • Lee, C.R.1    Goldstein, J.A.2    Pieper, J.A.3
  • 25
    • 24944503322 scopus 로고    scopus 로고
    • A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity
    • Yuan HY, Chen JJ, Lee MT, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet. 2005;14:1745-1751.
    • (2005) Hum Mol Genet , vol.14 , pp. 1745-1751
    • Yuan, H.Y.1    Chen, J.J.2    Lee, M.T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.